Isoniazid preventive therapy in HIV-infected children on antiretroviral therapy: A pilot study

International Journal of Tuberculosis and Lung Disease

Volumn 18, Issue 3, 2014, Pages 322-327

  Gray, D M ^a   Workman, L J ^a   Lombard, C J ^b   Jennings, T ^a   Innes, S ^c   Grobbelaar, C J ^d   Cotton, M F ^c   Zar, H J ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d ANOVA HEALTH INSTITUTE   (South Africa)

Author keywords

ART; IPT; Prophylaxis; TB

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ISONIAZID; TUBERCULOSTATIC AGENT;

AGE; CHILDHOOD MORTALITY; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPIDEMIOLOGY; FEMALE; HIV INFECTIONS; HUMAN; INFANT; INFANT MORTALITY; MALE; MIXED INFECTION; MORTALITY; MULTICENTER STUDY; PILOT STUDY; PRESCHOOL CHILD; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SOUTH AFRICA; TIME; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

AGE FACTORS; ANTI-HIV AGENTS; ANTITUBERCULAR AGENTS; CHILD MORTALITY; CHILD, PRESCHOOL; COINFECTION; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT MORTALITY; ISONIAZID; MALE; PILOT PROJECTS; PROSPECTIVE STUDIES; SOUTH AFRICA; TIME FACTORS; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY;

EID: 84894263868     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.13.0354     Document Type: Article

References (33)

1. UNAIDS World Aids Day report, 2011. Geneva, Switzerland: UNAIDS, 2011. http://www.unaids.org/en/media/unaids/content assets/documents/ unaidspublication/2011/JC2216-World AIDSday-report-2011-en.pdf Accessed November 2013.
2. World Health Organization. WHO report 2011: global tuberculosis control. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011.
3. Jeena P M, Pillay P, Pillay T, Coovadia H M. Impact of HIV-1 co-infection on presentation and hospital-related mortality in children with culture proven pulmonary tuberculosis in Durban, South Africa. Int J Tuberc Lung Dis 2002; 6: 672-678.
4. Zar H J, Hanslo D, Tannenbaum E, et al. Aetiology and outcome of pneumonia in human immunodeficiency virus-infected children hospitalized in South Africa. Acta Paediatr 2001; 90: 119-125.
5. Chintu C, Mudenda V, Lucas S, et al. Lung diseases at necropsy in African children dying from respiratory illnesses: a descriptive necropsy study. Lancet 2002; 360: 985-990.
6. Chintu C, Mwaba P. Tuberculosis in children with human immunodeficiency virus infection. Int J Tuberc Lung Dis 2005; 9: 477-484.
7. Palme I B, Gudetta B, Bruchfeld J, Muhe L, Giesecke J. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis. Pediatr Infect Dis J 2002; 21: 1053-1061.
8. Golub J E, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23: 631-636.
9. Edmonds A, Lusiama J, Napravnik S, Kitetele F, Van Rie A, Behets F. Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children. Int J Epidemiol 2009; 38: 1612-1621.
10. Martinson N A, Moultrie H, van Niekerk R, et al. HAART and risk of tuberculosis in HIV-infected South African children: a multi-site retrospective cohort. Int J Tuberc Lung Dis 2009; 13: 862-867.
11. Walters E, Cotton M F, Rabie H, Schaaf H S, Walters L O, Marais B J. Clinical presentation and outcome of tuberculosis in human immunodeficiency virus infected children on antiretroviral therapy. BMC Pediatrics 2008; 8: 1.
12. Madhi S A, Nachman S, Violari A, et al. Primary isoniazid prophylaxis against tuberculosis in HIV-exposed children. N Engl J Med 2011; 365: 21-31.
13. Smieja M J, Marchetti C A, Cook D J, Smaill F M. Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst Rev 2000: CD001363.
14. Samandari T, Agizew T B, Nyirenda S, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, doubleblind, placebo-controlled trial. Lancet 2011; 377: 1588-1598.
15. Zar H J, Cotton M F, Strauss S, et al. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ 2007; 334: 136.
16. Frigati L J, Kranzer K, Cotton M F, Schaaf H S, Lombard C J, Zar H J. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax 2011; 66: 496-501.
17. Rangaka M X, Boulle A, Wilkinson R J, et al. Randomized controlled trial of isoniazid preventive therapy in HIV-infected persons on antiretroviral therapy. Washington DC, USA: XIX International AIDS Conference, 2012.
18. South African Department of Health. The South African Tuberculosis Control Programme practical guidelines 2000. http:// www.westerncape.gov.za/ text/2003/tb-guidelines2000.pdf Accessed April 2013.
19. National Institute of Allergy and Infectious Diseases, Division of AIDS Regulatory Support Center, Safety and Pharmacovigilance Team. Division of AIDS table for grading the severity of adult and pediatric adverse events. Version 1.0, December 2004; clarification August 2009. http://rsc.tech-res.com/Document/ safetyandpharmacovigilance/Table-for-Grading-Severity-of- Adult-Pediatric- Adverse-Events.pdf Accessed April 2013.
20. Ren Y, Nuttall J J, Egbers C, et al. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 2008; 47: 566-569.
21. Zar H J, Lombard C. Isoniazid prophylaxis against tuberculosis in children. N Engl J Med 2011; 365: 1543; reply 1543-1544.
22. Marais B J, van Zyl S, Schaaf H S, van Aardt M, Gie R P, Beyers N. Adherence to isoniazid preventive chemotherapy: a prospective community based study. Arch Dis Child 2006; 91: 762-765.
23. Du Preez K, Hesseling A C, Mandalakas A M, Marais B J, Schaaf H S. Opportunities for chemoprophylaxis in children with culture-confirmed tuberculosis. Ann Trop Paediatr 2011; 31: 301-310.
24. Graham S M, Ahmed T, Amanullah F, et al. Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel. J Infect Dis 2012; 205 (Suppl): S199-S208.
25. Martinson N A, Barnes G L, Moulton L H, et al. New regimens to prevent tuberculosis in adults with HIV infection. N Engl J Med 2011; 365: 11-20.
26. Mosimaneotsile B, Mathoma A, Chengeta B, et al. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana experience, 2004-2006. J Acquir Immune Defic Syndr 2010; 54: 71-77.
27. Marais B J, Gie R P, Schaaf H S, Hesseling A C, Enarson D A, Beyers N. The spectrum of disease in children treated for tuberculosis in a highly endemic area. Int J Tuberc Lung Dis 2006; 10: 732-738.
28. le Roux S M, Cotton M F, Golub J E, le Roux D M, Workman L, Zar H J. Adherence to isoniazid prophylaxis among HIV-infected children: a randomized controlled trial comparing two dosing schedules. BMC Med 2009; 7: 67.
29. Muller A D, Bode S, Myer L, Roux P, von Steinbuchel N. Electronic measurement of adherence to pediatric antiretroviral therapy in South Africa. Pediatr Infect Dis J 2008; 27: 257-262.
30. Meissner P E, Musoke P, Okwera A, Bunn J E G, Coulter J B S. The value of urine testing for verifying adherence to antit uberculosis chemotherapy in children and adults in Uganda. Int J Tuberc Lung Dis 2002; 6: 903-908.
31. Szakacs T A, Wilson D, Cameron D W, et al. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. BMC Infect Dis 2006; 6: 97.
32. le Roux S M, Cotton M F, Myer L, et al. Safety of long-term isoniazid preventive therapy in children with HIV: a comparison of two dosing schedules. Int J Tuberc Lung Dis 2013; 17: 26-31.
33. Gray D, Nuttall J, Lombard C, et al. Low rates of hepatotoxicity in HIV-infected children on anti-retroviral therapy with and without isoniazid prophylaxis. J Trop Pediatr 2010; 56: 159-165.